266 related articles for article (PubMed ID: 15950667)
21. [HRT in post-menopausal women: endometrial histology and bleeding patterns].
Lo Dico G; Alongi G; Spinelli MP; Cannariato P; Lucido AM
Minerva Ginecol; 2002 Aug; 54(4):361-6. PubMed ID: 12114870
[TBL] [Abstract][Full Text] [Related]
22. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
[TBL] [Abstract][Full Text] [Related]
23. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet.
Weisberg E; Ayton R; Darling G; Farrell E; Murkies A; O'Neill S; Kirkegard Y; Fraser IS
Climacteric; 2005 Mar; 8(1):83-92. PubMed ID: 15804736
[TBL] [Abstract][Full Text] [Related]
24. Effects of subdermal implants of estradiol and testosterone on the endometrium of postmenopausal women.
Filho AM; Barbosa IC; Maia H; Genes CC; Coutinho EM
Gynecol Endocrinol; 2007 Sep; 23(9):511-7. PubMed ID: 17943546
[TBL] [Abstract][Full Text] [Related]
25. Transdermal progesterone cream as an alternative progestin in hormone therapy.
Leonetti HB; Landes J; Steinberg D; Anasti JN
Altern Ther Health Med; 2005; 11(6):36-8. PubMed ID: 16320858
[TBL] [Abstract][Full Text] [Related]
26. [Hormone replacement therapy with a transdermal estradiol gel and oral micronized progesterone. Effect on menopausal symptoms and lipid metabolism].
Giuliani A; Concin H; Wieser F; Boritsch J; Wilfert H; Gruber D; Urdl W
Wien Klin Wochenschr; 2000 Jul; 112(14):629-33. PubMed ID: 11008325
[TBL] [Abstract][Full Text] [Related]
27. Sequential combined transdermal and oral postmenopausal hormone replacement therapies: effects on bleeding patterns and endometrial histology.
Sendag F; Terek MC; Karadadas N
Arch Gynecol Obstet; 2001 Nov; 265(4):209-13. PubMed ID: 11789748
[TBL] [Abstract][Full Text] [Related]
28. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial.
Archer DF; Thorneycroft IH; Foegh M; Hanes V; Glant MD; Bitterman P; Kempson RL
Menopause; 2005; 12(6):716-27. PubMed ID: 16278615
[TBL] [Abstract][Full Text] [Related]
29. One year follow-up of hormone replacement therapy with percutaneous estradiol and low-dose vaginal natural progesterone in women with mild to moderate hypertension.
Spritzer PM; Vitola D; Vilodre LC; Wender MC; Reis FM; Ruschel S; Castro I
Exp Clin Endocrinol Diabetes; 2003 Aug; 111(5):267-73. PubMed ID: 12951632
[TBL] [Abstract][Full Text] [Related]
30. Continuous transdermal oestrogen and interrupted progestogen as a novel bleed-free regimen of hormone replacement therapy for postmenopausal women.
Cameron ST; Critchley HO; Glasier AF; Williams AR; Baird DT
Br J Obstet Gynaecol; 1997 Oct; 104(10):1184-90. PubMed ID: 9332998
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of vaginal estriol and progesterone in postmenopausal women with atrophic vaginitis.
Chollet JA; Carter G; Meyn LA; Mermelstein F; Balk JL
Menopause; 2009; 16(5):978-83. PubMed ID: 19390463
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics and endometrial effects of the vaginal administration of micronized progesterone in an oil-based solution to postmenopausal women.
Cicinelli E; Borraccino V; Petruzzi D; Mazzotta N; Cerundolo ML; Schönauer LM
Fertil Steril; 1996 Apr; 65(4):860-2. PubMed ID: 8654651
[TBL] [Abstract][Full Text] [Related]
33. Effect of oral administration of dydrogestrone versus vaginal administration of natural micronized progesterone on the secretory transformation of endometrium and luteal endocrine profile in patients with premature ovarian failure: a proof of concept.
Fatemi HM; Bourgain C; Donoso P; Blockeel C; Papanikolaou EG; Popovic-Todorovic B; Devroey P
Hum Reprod; 2007 May; 22(5):1260-3. PubMed ID: 17227809
[TBL] [Abstract][Full Text] [Related]
34. Effect of sequential transdermal progesterone cream on endometrium, bleeding pattern, and plasma progesterone and salivary progesterone levels in postmenopausal women.
Wren BG; McFarland K; Edwards L; O'Shea P; Sufi S; Gross B; Eden JA
Climacteric; 2000 Sep; 3(3):155-60. PubMed ID: 11910616
[TBL] [Abstract][Full Text] [Related]
35. Prevention of postmenopausal bone loss with long-cycle hormone replacement therapy.
Popp AW; Bodmer C; Senn C; Fuchs G; Kraenzlin ME; Wyss H; Birkhaeuser MH; Lippuner K
Maturitas; 2006 Jan; 53(2):191-200. PubMed ID: 16368472
[TBL] [Abstract][Full Text] [Related]
36. [A "no-bleeding" substitute hormone treatment with an oral microdose progesterone. A prospective multicenter study].
Gillet JY; Faguer B; André G; Magnin G; de Lignières B; Philippe E
J Gynecol Obstet Biol Reprod (Paris); 1994; 23(4):407-12. PubMed ID: 8051369
[TBL] [Abstract][Full Text] [Related]
37. Endometrial safety and bleeding patterns during a 2-year study of 1 or 2 mg 17 beta-estradiol combined with sequential 5-20 mg dydrogesterone.
Ferenczy A; Gelfand MM; van de Weijer PH; Rioux JE
Climacteric; 2002 Mar; 5(1):26-35. PubMed ID: 11974556
[TBL] [Abstract][Full Text] [Related]
38. Effects of ultralow-dose transdermal estradiol on postmenopausal symptoms in women aged 60 to 80 years.
Diem S; Grady D; Quan J; Vittinghoff E; Wallace R; Hanes V; Ensrud K
Menopause; 2006; 13(1):130-8. PubMed ID: 16607109
[TBL] [Abstract][Full Text] [Related]
39. Induction of amenorrhea during hormone replacement therapy: optimal micronized progesterone dose. A multicenter study.
Gillet JY; Andre G; Faguer B; Erny R; Buvat-Herbaut M; Domin MA; Kuhn JM; Hedon B; Drapier-Faure E; Barrat J
Maturitas; 1994 Aug; 19(2):103-15. PubMed ID: 7968643
[TBL] [Abstract][Full Text] [Related]
40. Comparison of the efficacy and tolerability of a new once-a-week matricial estradiol transdermal system (Estrapatch 40 and Estrapatch 60) with a twice week system.
Raynaud JP; Lévrier M; Calaf J; Laur C; Pélissier C
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):309-18. PubMed ID: 15860275
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
